Welcome to our dedicated page for Aditxt SEC filings (Ticker: ADTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Aditxt, Inc. (NASDAQ: ADTX) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed insight into how Aditxt describes its business as a social innovation platform accelerating promising health innovations, as well as its governance, capital structure, and key agreements.
Through Forms 10-K and 10-Q, investors can review Aditxt’s periodic financial statements and management discussions, including information about its programs in immune health, precision diagnostics, autoimmunity, cancer and early disease detection, infectious diseases, and women’s health. When Aditxt files a Form 12b-25 (NT 10-Q), it provides an explanation for delayed quarterly reports and indicates the expected timing of the filing.
Current reports on Form 8-K document material events such as the implementation of a 1-for-113 reverse stock split, amendments to the certificate of incorporation, entry into or termination of material definitive agreements, and financing arrangements. For example, Aditxt has used Form 8-K to report the approval and effectuation of its reverse stock split, the termination of its Amended and Restated Merger Agreement with Evofem Biosciences, Inc., and the issuance of notes and other securities.
Proxy statements on Schedule 14A (such as definitive proxy statements for special meetings) detail proposals submitted to stockholders, including approvals for issuances of common stock underlying various series of convertible preferred stock and warrants, the adoption of an Employee Stock Purchase Plan, amendments to the company’s equity incentive plan, authority to effect a reverse stock split, and a non-binding advisory vote on a proposed name change to “bitXbio, Inc.” These documents also describe meeting logistics and voting procedures.
Investors interested in ownership and governance can review information on security ownership of certain beneficial owners and management within proxy materials, while exhibits to Forms 8-K and other reports may include key agreements, amendments, and certificates of amendment. Stock Titan’s interface surfaces these filings as they appear on EDGAR and can pair them with AI-powered summaries that highlight the main points of lengthy documents, helping users quickly understand complex items such as capital structure changes, equity plans, and material contracts.
For those tracking insider and security-holder activity, related forms and disclosures filed by Aditxt and its insiders can be viewed alongside the company’s core reports. Together, these filings form the primary regulatory record of how Aditxt presents its strategy, risk factors, and significant corporate actions to the market.
Aditxt, Inc. (ADTX) is soliciting proxies for its 2025 annual meeting to be held virtually on September 16, 2025 at 12:00 PM ET. Stockholders of record as of August 8, 2025 (4,956,555 shares outstanding) may vote on four items: election of five directors, ratification of dbb mckennon as independent registered public accounting firm for fiscal 2025, authorization to grant the board discretionary authority to implement a reverse stock split at a ratio between 1-for-5 and 1-for-250 to be effective within one year if approved, and authorization to adjourn the meeting if needed.
The board proposes five nominees (Amro Albanna, Shahrokh Shabahang, Brian Brady, Charles Nelson, and Sylvia Hermina) and discloses board composition changes as two directors (Jeffrey Runge and Saundra Pelletier) are not standing for re-election, reducing the board from seven to five. Executive officer pay tables list 2024 base salaries including the CEO at $500,000 and other named officers. The proxy explains voting procedures, quorum (1,652,185 shares), broker voting rules, committee compositions, and director independence assessments consistent with Nasdaq standards.
Aditxt, Inc. (ADTX) disclosed two board members, Dr. Jeffrey Runge and Saundra Pelletier, will not stand for reelection at the 2025 Annual Meeting but will continue to serve until their terms expire. The company stated these decisions were not due to any disagreements with the company on operations, policies or practices.
The Board set the 2025 Annual Meeting for September 16, 2025 to be held virtually, with a record date of August 8, 2025. Because the meeting date changed by more than 30 days from last year, the prior proxy-statement nomination deadline no longer applies; the company established a submission deadline of August 18, 2025 for Rule 14a-8 proposals and for director nominations.
The filing also notes governance changes: the Board will be reduced from seven to five members after the meeting, and the company reiterated that Ms. Pelletier is expected to be appointed to the Board and as President of Adifem following the closing of the previously disclosed merger with Evofem per the Amended and Restated Merger Agreement dated July 12, 2024. The report includes a cautionary note that the proposed transaction may not be completed and lists related risks.
Aditxt has reported several significant financial transactions in this 8-K filing. Two senior executives provided short-term loans to the company: CEO Amro Albanna ($90,000) and CIO Shahrokh Shabahang ($100,000). These unsecured promissory notes carry a 7.5% interest rate and are due by July 20, 2025.
Additionally, the company issued a warrant to an unnamed consultant as part of a new marketing services agreement. Key warrant terms include:
- Right to purchase up to 600,000 shares of common stock
- Exercise price of $2.00 per share
- Two-year term
- Ownership limitation of 4.99% (or 9.99% at holder's election)
Both the promissory notes and warrant were issued under Section 4(a)(2) Securities Act exemption. The company, listed on Nasdaq as ADTX, is classified as an emerging growth company. These transactions suggest potential cash flow challenges and efforts to enhance investor relations.
Aditxt has filed an S-1 registration statement for the resale of up to 50 million shares of common stock under a $150 million purchase agreement with Seven Knots. The company has already sold 932,549 shares for approximately $23.9 million under this agreement.
Key business highlights:
- Founded in 2017, Aditxt focuses on transforming healthcare innovations into commercial products across immune health, precision health, population health, women's health, and neurologic health
- Business model involves securing innovations through licensing/acquisition, providing resources for development, and monetizing through commercialization
- Current commercial programs include Adimune (immune modulation technology) and Pearsanta (precision diagnostics)
- Company operates as a non-accelerated filer, smaller reporting company, and emerging growth company
The stock currently trades on Nasdaq under symbol ADTX at $1.42 per share (as of June 18, 2025). The company has implemented a digital asset treasury strategy that includes potential bitcoin investments. Notable partnerships include Stanford University and Mayo Clinic.